An open-labelled, international, multicenter, dose escalating, phase I/II study of SPC2996,an LNA antisense molecule against Bcl-2, in patients with relapsed or refractory chronic lymphocytic leukaemia.

Trial Profile

An open-labelled, international, multicenter, dose escalating, phase I/II study of SPC2996,an LNA antisense molecule against Bcl-2, in patients with relapsed or refractory chronic lymphocytic leukaemia.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 09 Nov 2012

At a glance

  • Drugs SPC 2996 (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Feb 2011 Actual end date (Dec 2007 ) added as reported by ClinicalTrials.gov.
    • 01 Feb 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top